Develops a non-invasive wearable for continuous blood glucose monitoring based on Raman spectroscopy.
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Series A Swiss Liom (formerly Spiden) extended its Series A by €13.9 million, bringing the round to €40.8 million, with support from existing investors and the entry of Red Bull Ventures. | $16.1M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.